Blog
Published January 29, 2024
Introduction
In the summer of 2023, many oncologists and cancer patients faced an impossible choice. Amidst many challenging treatment decisions, they had to determine how to proceed without two mainstays among oncology therapeutics: cisplatin and carboplatin. While it can sometimes be expected that there may be delays for the newest and most innovative treatments to reach patients, both cisplatin and carboplatin have been available for over twenty years, are used frequently in oncology regimens and are not considered particularly expensive.…
Read Now
Blog
Published January 12, 2024
Introduction
The Trinity Life Sciences’ team recently attended the 65th ASH Annual Meeting and Exposition from December 9-12, 2023, in San Diego, California. The conference brought together physicians, scientists and industry experts to share and collaborate on advances in understanding and treating blood cancers and blood disorders. Below are a few of the key insights that the Trinity team observed during the conference:
Advances in CAR-T Therapy: Expansion into New Targets and Therapeutic Areas
Numerous groups across the industry are…
Read Now
White Papers
This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance over three years of novel drugs approved by the FDA in 2020, with commercial, therapeutic value and R&D investment scores for each. 2020 saw 58 unique drug and biologic approvals, of which the majority were Oncology (29%) followed by Neurology…
Read Now
Webinars
Available On Demand
Join Trinity Life Sciences for a virtual lunch and learn where Krista Perry—Partner & Head of Launch Excellence, Curt Staab—Head of Client Development and Tarra Maeshima—Director of New Products & Strategy will demonstrate Trinity Launch Accelerator.
Launch project management office (PMO) teams and/or dedicated project manager (PM) resources are critical to enabling Launch Excellence-and the best support a PM can have is a single-source-of-truth launch planning and management tool that enables the integration necessary and takes work off everyone’s plate.…
Watch Now
Blog
Published December 18, 2023
First, A Few Potentially Unsettling Truths
Adoption and adaptation to Generative AI (GenAI) is a strategic imperative for pharma commercial insights departments if they want to maintain and enhance their relevance, impact, and strategic value within their organizations.
Organizations are increasingly data-driven; market research teams that do not leverage AI will struggle to provide the timely, nuanced insights that modern pharma marketing organizations demand, diminishing their role in critical decision-making processes.
Top talent gravitates towards innovation. Departments that fail to…
Read Now
Briefs
Highlights from TGaS Advisors’ Fall Summit
How are Biopharmaceutical organizations evolving to develop capabilities and propel innovation for 2024 and beyond?
Executive leaders in Commercial Operations, Medical Affairs and Market Access are focused on making informed decisions to propel the evolution of their organizations in this rapidly changing global economy. As you strategize to accelerate optimizing structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ Fall Summit.…
Read Now
White Papers
Cell therapies are becoming increasingly incorporated as late-line standards of care across relapsed/refractory oncology indications, with an expanding ability to improve outcomes for a diverse set of tumors and patient subgroups. As the next frontier of personalized and precision medicine continues to grow, Natural Killer (NK) cell therapies offer the potential to penetrate untapped needs across a variety of cancers. However, enthusiasm surrounding the opportunity offered by NK-based technologies has fluctuated over recent years. Several large pharma leaders have made…
Read Now
Blog
Published December 7, 2023
Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both academics and the life sciences industry, including manufacturers, regulatory leaders and health economists, to consider the latest challenges and opportunities being addressed by health economics and outcomes research. Topics included Joint Clinical Assessments (JCAs), access to innovative therapies, environmental…
Read Now
Blog
Published November 17, 2023
Introduction
The Trinity team recently attended the Milken Institute’s 2023 Future of Health Summit in Washington, DC. Its theme was “Closing the Gap” in healthcare – as chronic disease becomes more prevalent worldwide and the average life expectancy in the US declines to its lowest level since the early 1990’s, what can be done? The sessions explored how industry leaders, government officials, nonprofits, and patients can work together to reverse the declining and diverging metrics we see in healthcare outcomes…
Read Now
Scientific Publications
Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe
Acosta Luis S1, O’Hara M2, Yeh M2
1Trinity Partners, LLC, London, UK, 2Trinity Life Sciences, Waltham, MA, USA
The EU-wide Joint Clinical Assessment (JCA) is set to be operational from January 2025. The Trinity team reviewed the available literature and summarized the JCA implications for medical device launch planning and evidence-generation requirements, including the central role that HEOR expertise across different geographies will…
Read Now
